Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in Western countries and a significant factor in hepatocellular carcinoma (HCC), cardiovascular issues, and overall mortality [1, 2]
Klinic streamlines the process, covering insurance, handling authorizations, and ensuring maximum convenience
There are all these different potential mechanisms of action, which are all basically just that they help neurons to survive, Rascol says
One notable difference is that tirzepatide is a dual-agonist (GLP-1 and GIP) while retatrutide is a triple-agonist (GLP-1, GIP, and glucagon)